Stocks TelegraphStocks Telegraph
Screener NEW

Celsion Corporation (CLSN) stock went down after the Financial results announcement

By Asim Kamal
Published On March 22, 2021 6:25 AM UTC
Celsion Corporation (CLSN) stock went down after the Financial results announcement

The CLNS stock sinks 5.36% in Friday’s after-market session following the financial results were released. Despite beating the revenue estimates, Celsion stock faced negativity. Let’s have a look at their financial figures.

Financial Highlights for the full-year 2020

  • CLSN reported a net loss of $21.5 million or $0.67 per share for the reported year, compared to a net loss of $16.8 million or $0.77 per share in 2019.
  • General and administrative expenses were $7.6 million in 2020, compared with $8.0 million in 2019
  • Celsion Corporation spent $11.3 million in Research and development expenses in 2020 compared to $13.1 million in 2019.
  • As of December 31, 2020, Cash, cash equivalents and were $17.2 million.

Recent Developments

The CLSN provided an update on its GEN-1, DNA-based immunotherapy in Phase I/II development for the localized treatment of ovarian cancer. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT). After three cycles of chemotherapy, NACT is designed to shrink cancer as much as possible for optimal surgical removal. The GEN-1 also received Fast Track designation from the FDA. Fast Track designation is intended to facilitate the development and accelerate the regulatory review of drugs to treat serious conditions and fill an unmet medical need.

The CLSN also filed a provisional U.S. patent application on January 28, 2021, for a novel DNA-based, investigational vaccine for preventing or treating infections from a broad range of infectious agents, including coronaviruses, using its PLACCINE DNA vaccine technology platform.

About CLSN

Celsion Corporation is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Celsion’s lead product candidate is ThermoDox, and 2nd one is in the pipeline known as GEN-1.

Michael H. Tardugno is the company’s Chairman, President and Chief Executive Officer. He began his career in 1977 with Abbott Laboratories and has 30 years of experience in the pharmaceutical and medical device industries. He holds a B.S. in Biology from St. Bonaventure University and completed the Harvard Business School executive program.

Conclusion:Despite the recent uncompellingresults, CLSN can attract investors based on its improved clinical trial results of GEN-1.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph